Applying Lucentis for the treatment of retinopathy of prematurity
Purpose: to evaluate the efficacy of Lucentis for the treatment of retinopathy of prematurity (ROP). Material and methods. 51 infants (102 eyes) with the gestational age between 24 and 33 weeks were given intravitreal injections of Lucentis, All patients selected had ROP stages I+, II+, III or III+...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2022-12-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/1096 |
| _version_ | 1826569901351895040 |
|---|---|
| author | S. V. Lesovoy O. A. Boginskaya |
| author_facet | S. V. Lesovoy O. A. Boginskaya |
| author_sort | S. V. Lesovoy |
| collection | DOAJ |
| description | Purpose: to evaluate the efficacy of Lucentis for the treatment of retinopathy of prematurity (ROP). Material and methods. 51 infants (102 eyes) with the gestational age between 24 and 33 weeks were given intravitreal injections of Lucentis, All patients selected had ROP stages I+, II+, III or III+ in zone 1, stage III+ in zone 2, or aggressive posterior ROP. The procedure was performed under general anesthesia; the dose, technique and the number of Lucentis injections conformed with the recommendations given in Lucentis instruction for use. If indicated, retinal laser photocoagulation was given after intravitreal injections using Supra (Quantel Medical, France) and Lachta-Mylon (Russia, Lasermedservis) laser equipment. Results. Clinical efficacy of intravitreal administration of Ranibizumab in infants with aggressive posterior ROP, zone 1 ROP, Stage III of zone 2 ROP was determined at 86.3 % (with no more than two injections). If ROP remains active after two injections, a change of therapy is recommended. Vascularization was noted to be complete in 51 % of cases. Conclusion. To achieve a maximum treatment effect of ROP with Lucentis, strict observation of indications criteria must take place. |
| first_indexed | 2024-04-10T02:30:56Z |
| format | Article |
| id | doaj.art-e979c53f506640558a452d8241ed76db |
| institution | Directory Open Access Journal |
| issn | 2072-0076 2587-5760 |
| language | Russian |
| last_indexed | 2025-03-14T11:46:42Z |
| publishDate | 2022-12-01 |
| publisher | Real Time Ltd |
| record_format | Article |
| series | Российский офтальмологический журнал |
| spelling | doaj.art-e979c53f506640558a452d8241ed76db2025-03-02T09:51:29ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602022-12-01154454810.21516/2072-0076-2022-15-4-45-48520Applying Lucentis for the treatment of retinopathy of prematurityS. V. Lesovoy0O. A. Boginskaya1Z.A. Bashlyaeva Children's City Clinical HospitalZ.A. Bashlyaeva Children's City Clinical HospitalPurpose: to evaluate the efficacy of Lucentis for the treatment of retinopathy of prematurity (ROP). Material and methods. 51 infants (102 eyes) with the gestational age between 24 and 33 weeks were given intravitreal injections of Lucentis, All patients selected had ROP stages I+, II+, III or III+ in zone 1, stage III+ in zone 2, or aggressive posterior ROP. The procedure was performed under general anesthesia; the dose, technique and the number of Lucentis injections conformed with the recommendations given in Lucentis instruction for use. If indicated, retinal laser photocoagulation was given after intravitreal injections using Supra (Quantel Medical, France) and Lachta-Mylon (Russia, Lasermedservis) laser equipment. Results. Clinical efficacy of intravitreal administration of Ranibizumab in infants with aggressive posterior ROP, zone 1 ROP, Stage III of zone 2 ROP was determined at 86.3 % (with no more than two injections). If ROP remains active after two injections, a change of therapy is recommended. Vascularization was noted to be complete in 51 % of cases. Conclusion. To achieve a maximum treatment effect of ROP with Lucentis, strict observation of indications criteria must take place.https://roj.igb.ru/jour/article/view/1096retinopathy of prematurityvascular endothelial growth factor inhibitorslucentisretinal photocoagulation |
| spellingShingle | S. V. Lesovoy O. A. Boginskaya Applying Lucentis for the treatment of retinopathy of prematurity Российский офтальмологический журнал retinopathy of prematurity vascular endothelial growth factor inhibitors lucentis retinal photocoagulation |
| title | Applying Lucentis for the treatment of retinopathy of prematurity |
| title_full | Applying Lucentis for the treatment of retinopathy of prematurity |
| title_fullStr | Applying Lucentis for the treatment of retinopathy of prematurity |
| title_full_unstemmed | Applying Lucentis for the treatment of retinopathy of prematurity |
| title_short | Applying Lucentis for the treatment of retinopathy of prematurity |
| title_sort | applying lucentis for the treatment of retinopathy of prematurity |
| topic | retinopathy of prematurity vascular endothelial growth factor inhibitors lucentis retinal photocoagulation |
| url | https://roj.igb.ru/jour/article/view/1096 |
| work_keys_str_mv | AT svlesovoy applyinglucentisforthetreatmentofretinopathyofprematurity AT oaboginskaya applyinglucentisforthetreatmentofretinopathyofprematurity |